Merck & Company Inc (MRK)vsVanda Pharmaceuticals Inc (VNDA)
MRK
Merck & Company Inc
$148.78
+0.54%
HEALTHCARE · Cap: $365.34B
VNDA
Vanda Pharmaceuticals Inc
$5.05
+1.41%
HEALTHCARE · Cap: $310.17M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 30759% more annual revenue ($66.57B vs $215.72M). MRK leads profitability with a 4.8% profit margin vs -127.4%. VNDA appears more attractively valued with a PEG of 2.23. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
VNDA
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.2%
Fair Value
$83.04
Current Price
$148.78
$65.74 premium
Margin of Safety
+82.9%
Fair Value
$35.79
Current Price
$5.05
$30.74 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.8x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -60.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : VNDA
The strongest argument for VNDA centers on Price/Book, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : VNDA
The primary concerns for VNDA are PEG Ratio, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while VNDA is a turnaround play — different risk/reward profiles.
VNDA carries more volatility with a beta of 0.65 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 35/100). VNDA offers better value entry with a 82.9% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Vanda Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?